[go: up one dir, main page]

MX2023007193A - Inhibidores de enpp1 y su uso para el tratamiento del cancer. - Google Patents

Inhibidores de enpp1 y su uso para el tratamiento del cancer.

Info

Publication number
MX2023007193A
MX2023007193A MX2023007193A MX2023007193A MX2023007193A MX 2023007193 A MX2023007193 A MX 2023007193A MX 2023007193 A MX2023007193 A MX 2023007193A MX 2023007193 A MX2023007193 A MX 2023007193A MX 2023007193 A MX2023007193 A MX 2023007193A
Authority
MX
Mexico
Prior art keywords
enpp1
subject
cancer
methods
inhibitor
Prior art date
Application number
MX2023007193A
Other languages
English (en)
Inventor
Mark Smith
Lingyin Li
Kelsey Erin Shaw
Jacqueline Ann Carozza
Volker Boehnert
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2023007193A publication Critical patent/MX2023007193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos, composiciones y métodos para la inhibición de ENPP1. Aspectos de los métodos de la presente incluyen poner en contacto una muestra con un inhibidor de ENPP1 para inhibir la actividad de hidrólisis de cGAMP de ENPP1. En algunos casos, el inhibidor de ENPP1 es impermeable a las células. También se proporcionan composiciones y métodos para tratar el cáncer. Aspectos de los métodos incluyen administrarle a un sujeto una cantidad terapéuticamente eficaz de un inhibidor de ENPP1 para tratar el cáncer del sujeto. En determinados casos, el cáncer es un cáncer de tumor sólido. También se proporcionan métodos para administrar radioterapia a un sujeto ya sea antes o después de administrar un inhibidor de ENPP1. La radioterapia puede administrarse a una dosificación y/o frecuencia eficaz para reducir el daño de radiación al sujeto. En determinados casos, el método se realiza en combinación con un agente quimioterapéutico, o un inhibidor del punto de control o ambos.
MX2023007193A 2017-09-08 2020-03-06 Inhibidores de enpp1 y su uso para el tratamiento del cancer. MX2023007193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762556117P 2017-09-08 2017-09-08

Publications (1)

Publication Number Publication Date
MX2023007193A true MX2023007193A (es) 2023-07-03

Family

ID=63714052

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002646A MX2020002646A (es) 2017-09-08 2018-09-07 Inhibidores de enpp1 y su uso para el tratamiento del cancer.
MX2023007193A MX2023007193A (es) 2017-09-08 2020-03-06 Inhibidores de enpp1 y su uso para el tratamiento del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002646A MX2020002646A (es) 2017-09-08 2018-09-07 Inhibidores de enpp1 y su uso para el tratamiento del cancer.

Country Status (18)

Country Link
US (3) US11701371B2 (es)
EP (2) EP4327882A3 (es)
JP (2) JP7292740B2 (es)
KR (2) KR20240151869A (es)
CN (2) CN117883449A (es)
AU (2) AU2018330188C1 (es)
BR (1) BR112020004559A2 (es)
CA (1) CA3074268A1 (es)
DK (1) DK3678668T3 (es)
EA (1) EA202090595A1 (es)
ES (1) ES2975183T3 (es)
HU (1) HUE066413T2 (es)
IL (3) IL311010A (es)
MA (1) MA50082A (es)
MX (2) MX2020002646A (es)
PL (1) PL3678668T3 (es)
SG (1) SG11202001728YA (es)
WO (1) WO2019051269A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020140001A1 (en) * 2018-12-28 2020-07-02 Riboscience Llc Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
JP7598875B2 (ja) 2019-04-12 2024-12-12 リボサイエンス リミティド ライアビリティ カンパニー エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体
BR112022004809A2 (pt) 2019-09-16 2022-06-21 Aten Porus Lifesciences Pvt Ltd Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1
WO2021061803A1 (en) * 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
IL295257A (en) * 2020-02-04 2022-10-01 Stingray Therapeutics Inc Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of using them
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
WO2021203772A1 (en) * 2020-04-09 2021-10-14 Betta Pharmaceuticals Co., Ltd Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof
CA3182410A1 (en) * 2020-05-04 2021-11-11 Volastra Therapeutics, Inc. Imino sulfanone inhibitors of enpp1
WO2021225407A1 (ko) 2020-05-08 2021-11-11 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
KR102682428B1 (ko) 2020-05-08 2024-07-05 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
WO2021257614A1 (en) * 2020-06-16 2021-12-23 Volastra Therapeutics, Inc. Heterocyclic inhibitors of enpp1
BR112023003948A2 (pt) 2020-09-03 2023-04-11 Immunesensor Therapeutics Inc Compostos de antagonista de quinolina cgas
CA3200318A1 (en) * 2020-10-30 2022-05-05 1Cbio, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
CN116600813A (zh) * 2020-12-09 2023-08-15 斯汀格瑞治疗股份有限公司 作为enpp1和cdnp抑制剂的膦酸盐
US20250099493A1 (en) * 2020-12-09 2025-03-27 Stingray Therapeutics, Inc. Phosphonates as inhibitors of enpp1 and cdnp
KR102720206B1 (ko) 2020-12-29 2024-10-21 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
CA3200386A1 (en) 2020-12-29 2022-07-07 Seo Jung Han Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof
MX2023008761A (es) 2021-01-29 2023-08-22 Txinno Bioscience Inc Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo.
KR102686866B1 (ko) 2021-01-29 2024-07-19 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
US20240209005A1 (en) * 2021-03-16 2024-06-27 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
AU2022256476A1 (en) 2021-04-16 2023-10-12 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN115536696B (zh) * 2021-06-29 2023-07-14 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023035001A1 (en) * 2021-09-03 2023-03-09 Angarus Therapeutics, Inc. Enpp1 inhibitors and immune cells expressing chimeric antigen receptors
WO2023077083A1 (en) * 2021-10-29 2023-05-04 Angarus Therapeutics, Inc. Enpp1 inhibitors as inhibitors of metastasis
KR20250004639A (ko) 2022-03-02 2025-01-08 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cGAS 길항제 화합물
CN118488950A (zh) * 2022-04-11 2024-08-13 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
WO2023212154A1 (en) 2022-04-29 2023-11-02 Petragen, Inc. Inhibitors of enpp1 and modulation of bone growth
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
CN119677742A (zh) * 2022-08-01 2025-03-21 斯拉瓦蒂人工智能科技私人有限公司 一种新型外核苷酸焦磷酸酶/磷酸二酯酶1（enpp1）抑制剂及其用途
WO2024213932A1 (en) * 2023-04-11 2024-10-17 The Hong Kong University Of Science And Technology Driving axon regeneration by novel enpp1 inhibitors
WO2024216211A2 (en) * 2023-04-14 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Methods of inhibiting tumor progression and metastasis by inhibition of enpp1

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA228044A (en) 1923-01-16 Thomas Noble Boughton Die for forming bolts
CA190896A (en) 1919-02-24 1919-06-17 Josephat C. Bergeron Advertising device
DE3319795A1 (de) 1983-06-01 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von phosphonsaeureestern
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
AU704973B2 (en) 1995-04-21 1999-05-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU2002254152A1 (en) * 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
DE60328735D1 (de) 2002-12-24 2009-09-17 Astrazeneca Ab Chinazolinderivate
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PL2621923T3 (pl) * 2010-09-29 2017-08-31 Intervet International B.V. Związki n-heteroarylu z mostkami cyklicznymi do leczenia chorób pasożytniczych
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
WO2016048861A2 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Heterocyclic compounds and use thereof
WO2016049568A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
CN105153153A (zh) 2015-08-31 2015-12-16 吉林奥来德光电材料股份有限公司 一种新的芳香族胺类化合物及其制备与应用
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
US20200085782A1 (en) 2016-12-22 2020-03-19 Mavupharma, Inc. Compositions and methods of enhancing or augmenting type i ifn production
WO2018127928A1 (en) 2017-01-09 2018-07-12 The Australian National University Synergists for improved pesticides
US10518257B2 (en) 2017-05-04 2019-12-31 Exxonmobil Research And Engineering Company Metal organic frameworks, their synthesis and use
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
WO2019046778A1 (en) 2017-08-31 2019-03-07 Mavupharma, Inc. INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP-1) AND USES THEREOF
CN113677350B (zh) 2019-02-01 2025-01-14 里兰斯坦福初级大学理事会 Enpp1抑制剂和调节免疫反应的方法
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Also Published As

Publication number Publication date
EP4327882A3 (en) 2024-05-15
IL272948A (en) 2020-04-30
EA202090595A1 (ru) 2020-06-29
KR20200066292A (ko) 2020-06-09
IL302338B1 (en) 2024-06-01
AU2018330188C1 (en) 2024-02-29
IL272948B2 (en) 2023-09-01
US20210369747A1 (en) 2021-12-02
HUE066413T2 (hu) 2024-08-28
JP2020533288A (ja) 2020-11-19
IL272948B1 (en) 2023-05-01
CN117883449A (zh) 2024-04-16
CN111372587B (zh) 2024-01-09
BR112020004559A2 (pt) 2020-09-24
US20230277570A1 (en) 2023-09-07
KR20240151869A (ko) 2024-10-18
JP7607969B2 (ja) 2025-01-06
IL302338A (en) 2023-06-01
AU2024200148A1 (en) 2024-01-25
MX2020002646A (es) 2020-09-25
AU2018330188B2 (en) 2023-10-19
EP3678668B1 (en) 2024-01-10
IL302338B2 (en) 2024-10-01
CN111372587A (zh) 2020-07-03
WO2019051269A1 (en) 2019-03-14
MA50082A (fr) 2020-07-15
DK3678668T3 (da) 2024-04-08
EP3678668A1 (en) 2020-07-15
US20230103498A1 (en) 2023-04-06
SG11202001728YA (en) 2020-03-30
CA3074268A1 (en) 2019-03-14
AU2018330188A1 (en) 2020-04-23
JP2023101715A (ja) 2023-07-21
US11701371B2 (en) 2023-07-18
KR102715420B1 (ko) 2024-10-10
US11707471B2 (en) 2023-07-25
ES2975183T3 (es) 2024-07-03
RU2020112299A3 (es) 2022-03-14
IL311010A (en) 2024-04-01
EP4327882A2 (en) 2024-02-28
JP7292740B2 (ja) 2023-06-19
RU2020112299A (ru) 2021-10-08
PL3678668T3 (pl) 2024-06-03

Similar Documents

Publication Publication Date Title
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
PH12021551833A1 (en) Enpp1 inhibitors and methods of modulating immune response
MX2023002248A (es) Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
ZA201906001B (en) Combination therapy for the treatment or prevention of tumours
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
WO2018102687A3 (en) Combination therapy for treating cancer
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
EA201391286A1 (ru) Лечение солидных опухолей
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
EP4299127A3 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
ZA201901367B (en) Inhibition of olig2 activity
BR112022009794A2 (pt) Método para tratar câncer no pulmão
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2021006778A (es) Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.